Determines the frequency of MDM2 and TP53 gene abnormalities in bladder tumors. Patient characteristics and tissues; Monoclonal antibodies and immunohistochemistry; Southern blotting for MDM2 amplification; SSCP analysis and DNA sequencing for TP53 mutations; Altered genotype and phenotype of MDM2 and TP53.